1887
  1. Home
  2. Eurosurveillance
  3. Volume 29, Issue 10, 07/Mar/2024
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23–55) in 18–59-year-olds and 50% (95% CI: 44–56) in 60–85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2–6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI:0.8–2.6).

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.10.2400109
2024-03-07
2024-12-19
/content/10.2807/1560-7917.ES.2024.29.10.2400109
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/10/eurosurv-29-10-2.html?itemId=/content/10.2807/1560-7917.ES.2024.29.10.2400109&mimeType=html&fmt=ahah

References

  1. Centers for Disease Control and Prevention (CDC). COVID-19 activity increases as prevalence of JN.1 variant continues to rise. Atlanta: CDC; 2024. Available from: https://www.cdc.gov/respiratory-viruses/whats-new/JN.1-update-2024-01-05.html
  2. Looi M-K. Covid-19: WHO adds JN.1 as new variant of interest. BMJ. 2023;383:2975.  https://doi.org/10.1136/bmj.p2975  PMID: 38128957 
  3. Kaku Y, Okumura K, Padilla-Blanco M, Kosugi Y, Uriu K, Hinay AA Jr, et al. Virological characteristics of the SARS-CoV-2 JN.1 variant.[PREPRINT]. bioRxiv2023:2023.12.08.570782 https://doi.org/10.1101/2023.12.08.570782 
  4. Andeweg SP, de Gier B, Eggink D, van den Ende C, van Maarseveen N, Ali L, et al. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections. Nat Commun. 2022;13(1):4738.  https://doi.org/10.1038/s41467-022-31838-8  PMID: 35961956 
  5. Rector A, Bloemen M, Schiettekatte G, Maes P, Van Ranst M, Wollants E. Sequencing directly from antigen-detection rapid diagnostic tests in Belgium, 2022: a gamechanger in genomic surveillance? Euro Surveill. 2023;28(9):2200618.  https://doi.org/10.2807/1560-7917.ES.2023.28.9.2200618  PMID: 36862099 
  6. Huiberts AJ, Kooijman MN, de Melker HE, Hahne SJ, Grobbee DE, Hoeve C, et al. Design and baseline description of an observational population-based cohort study on COVID-19 vaccine effectiveness in the Netherlands - The VAccine Study COvid-19 (VASCO).[PREPRINT]. Research Square. 2022 https://doi.org/10.21203/rs.3.rs-1645696/v1 
  7. Huiberts AJ, de Gier B, Hoeve CE, de Melker HE, Hahné SJM, den Hartog G, et al. Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study. Int J Infect Dis. 2023;133:36-42.  https://doi.org/10.1016/j.ijid.2023.04.401  PMID: 37086863 
  8. Rijksoverheid. Virusdeeltjes in rioolwater. [Virus particles in wastewater]. Den Haag: Rijksoverheid. [Accessed: 8 Jan 2024]. Dutch. Available from: https://coronadashboard.government.nl/landelijk/rioolwater
  9. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). Actuele resultaten Infectieradar. [Current results Infection radar]. Bilthoven: RIVM. [Accessed: 8 Jan 2024]. Dutch. Available from: https://www.infectieradar.nl/results
  10. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). Varianten van het coronavirus SARS-CoV-2. [Variants of the coronavirus SARS-CoV-2]. Bilthoven: RIVM. [Accessed: 12 Jan 2024]. Dutch. Available from: https://www.rivm.nl/coronavirus-covid-19/virus/varianten
  11. Link-Gelles R, Ciesla AA, Mak J, Miller JD, Silk BJ, Lambrou AS, et al. Early estimates of updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating Omicron variants among immunocompetent adults - increasing community access to testing program, United States, September 2023-January 2024. MMWR Morb Mortal Wkly Rep. 2024;73(4):77-83.  https://doi.org/10.15585/mmwr.mm7304a2  PMID: 38300853 
  12. Link-Gelles R, Ciesla AA, Fleming-Dutra KE, Smith ZR, Britton A, Wiegand RE, et al. Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection - increasing community access to testing program, United States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1526-30.  https://doi.org/10.15585/mmwr.mm7148e1  PMID: 36454688 
  13. Huiberts AJ, de Gier B, Hoeve CE, de Melker HE, Hahné SJ, den Hartog G, et al. Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022. Euro Surveill. 2023;28(7):2300087.  https://doi.org/10.2807/1560-7917.ES.2023.28.7.2300087  PMID: 36795500 
  14. Modjarrad K, Che Y, Chen W, Wu H, Cadima CI, Muik A, et al. Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine.[PREPRINT]. bioRxiv. 2023:2023.11.17.567633 https://doi.org/10.1101/2023.11.17.567633 
  15. Wang Q, Guo Y, Bowen A, Mellis IA, Valdez R, Gherasim C, et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants.[PREPRINT]. bioRxiv. 2023:2023.11.26.568730 https://doi.org/10.1101/2023.11.26.568730 
  16. Wang Q, Guo Y, Liu L, Schwanz LT, Li Z, Nair MS, et al. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature. 2023;624(7992):639-44.  https://doi.org/10.1038/s41586-023-06750-w  PMID: 37871613 
  17. Moustsen-Helms IR, Bager P, Graakjær Larsen T, Møller FT, Skafte Vestergaard L, Engbo Christiansen L, et al. Relative vaccine protection, disease severity and symptoms associated with infection with SARS-CoV-2 Omicron subvariant Ba.2.86 and descendent Jn.1: A Danish nationwide register-based study.[PREPRINT]. SSRN. 2024 https://doi.org/10.2139/ssrn.4716761 
  18. Hansen CH, Moustsen-Helms IR, Rasmussen M, Søborg B, Ullum H, Valentiner-Branth P. Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study. Lancet Infect Dis. 2024;24(2):e73-4.  https://doi.org/10.1016/S1473-3099(23)00746-6  PMID: 38190834 
  19. van Werkhoven CH, Valk A-W, Smagge B, de Melker HE, Knol MJ, Hahné SJ, et al. Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023. Euro Surveill. 2024;29(1):2300703.  https://doi.org/10.2807/1560-7917.ES.2024.29.1.2300703  PMID: 38179623 
Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Anne+J+Huiberts&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Huiberts Anne J</a>, <a href="/search?value1=Christina+E+Hoeve&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hoeve Christina E</a>, <a href="/search?value1=Brechje+de+Gier&option1=author&noRedirect=true" class="nonDisambigAuthorLink">de Gier Brechje</a>, <a href="/search?value1=Jeroen+Cremer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cremer Jeroen</a>, <a href="/search?value1=Bas+van+der+Veer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van der Veer Bas</a>, <a href="/search?value1=Hester+E+de+Melker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">de Melker Hester E</a>, <a href="/search?value1=Janneke+HHM+van+de+Wijgert&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van de Wijgert Janneke HHM</a>, <a href="/search?value1=Susan+van+den+Hof&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van den Hof Susan</a>, <a href="/search?value1=Dirk+Eggink&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Eggink Dirk</a>, <a href="/search?value1=Mirjam+J+Knol&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Knol Mirjam J</a></span>. Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024. <a href="/content/ecdc">Euro Surveill.</a> 2024;29(10):pii=2400109. <a href="https://doi.org/10.2807/1560-7917.ES.2024.29.10.2400109" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2024.29.10.2400109</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 15 Feb 2024;&nbsp;&nbsp; <span class="generated">Accepted</span>: 04 Mar 2024 </span> </p>
/content/10.2807/1560-7917.ES.2024.29.10.2400109
/content/10.2807/1560-7917.ES.2024.29.10.2400109
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error